Wilcrest Pharma
- Company typePrivate
- Founded2024
- HeadquartersHouston, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Wilcrest Pharma does
Wilcrest Pharmaceuticals, Inc. (Wilcrest Pharma) is an FDA-registered 503B outsourcing facility headquartered in Houston, Texas, that compounds sterile and non-sterile medications for external healthcare customers. The company was founded in 2024 by pharmacist A.J. Day, PharmD, who brings more than 17 years of compounding experience and was recognized as a 2022 Compounding Advocacy Champion. Operations run out of a purpose-built 60,000 sqft facility containing 11,000 sqft of controlled production space organized into custom cleanrooms with 24/7 environmental monitoring, operating to current Good Manufacturing Practice (CGMP) standards.
The product portfolio spans six lines: oncology, cardiology, ENT, transplant, custom products, and Contract Development Manufacturing (CDM) services, covering both hazardous and non-hazardous sterile preparations as well as non-sterile compounds. Products are sold under Wilcrest's own label as compounded medications, while the CDM line provides fee-for-service development and manufacturing for external sponsors. Pricing is quote-based rather than list-based, and customer relationships are structured as multi-year contracts.
Wilcrest goes to market through a direct B2B sales model targeting hospital pharmacies, infusion centers, outpatient surgery centers, veterinary clinics, and research institutions across the United States. The company does not disclose named customer accounts, contract values, or unit volumes in available material. Its headcount is reported in the 1–10 employee range, consistent with an early-commercial-stage operation. No outside funding rounds, investors, or revenue figures have been disclosed.
Wilcrest Pharma firmographics
Firmographics- Name
- Wilcrest Pharma
- Legal name
- Wilcrest Pharmaceuticals, Inc.
- Website
- https://wilcrestpharma.com
- Company type
- Private
- Founded year
- 2024
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Wilcrest Pharma industry classification
Industry- Product category
- Compounded Pharmaceutical Manufacturing
- NAICS
- Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI)
- akta.pro secondary industries
- Specialty Care Pharmaceuticals (HLAIAAAB), Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)
Keywords
Where Wilcrest Pharma is headquartered
LocationHeadquarters
- HQ city
- Houston
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Wilcrest Pharma business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Infrastructure, Supply Chain, Operations, Technology or R&D, Marketing or Sales
Revenue model
- Compounded Pharmaceutical Products: Wilcrest Pharma generates revenue through the sale of compounded medications, including hazardous drugs, oncology medications, and other challenging formulations. As a 503B outsourcing facility, they supply these medications directly to healthcare organizations through their order portal after account registration. The company also offers contract development manufacturing services for organizations seeking partnership in product development from formulation research to product release.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Custom pharmaceutical compounding services for healthcare organizations |
Go-to-market motion2 records
Distribution channels2 records
Marketing channels3 records
Wilcrest Pharma product offering
Product offeringCore offering
Wilcrest Pharma operates an FDA-registered 503B outsourcing facility that formulates complex sterile and non-sterile compounded medications for healthcare organizations. The portfolio spans oncology (antineoplastic) medications, cardiology, ENT, transplant formulations, custom-developed products, and full contract development manufacturing services from formulation research through product release.
Product overview
Wilcrest Pharma operates as a single integrated platform offering compounded pharmaceutical products through a 503B outsourcing facility model. The portfolio consists of six core product/service offerings: Oncology (antineoplastic medications), Cardiology, ENT, Transplant, Custom Products, and Contract Development Manufacturing. These offerings are unified by the company's foundational expertise in clinical and technical formulation creation and CGMP-compliant manufacturing capabilities. The products range from ready-to-use hazardous medications for oncology treatment to temperature-stable transplant medications, all supported by the company's 60,000 sqft CGMP-compliant facility with over 11,000 sqft of controlled production space.
Differentiator
Problem solved
Functional benefit
Products and services
- Oncology (Antineoplastic Medications)
Companies that use Wilcrest Pharma
Customer profileSegments7 records
Ideal customer profiles6 records
Wilcrest Pharma technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Wilcrest Pharma partnerships and signals
Strategic signalScale indicators4 records
Recent moves6 records
Expansion highlights5 records
Wilcrest Pharma competitors and assessment
Company assessmentDirect peers
- Fagron (503B division, including Pillar5): Fagron operates 503B outsourcing facilities through acquisitions such as Pillar5, producing sterile and non-sterile compounded preparations for hospitals and clinics across North America. The 503B arm is one of Wilcrest's closest scaled competitors in CGMP compounding.
- AnazaoHealth: AnazaoHealth is an FDA-registered 503B outsourcing facility specializing in sterile injectable compounding, including hazardous and non-hazardous preparations for hospitals and clinics. Its product mix and direct-to-hospital model directly mirror Wilcrest's offerings.
- Stokes Healthcare (Triad): Stokes Healthcare operates as part of the Triad family of 503B outsourcing facilities producing sterile-to-use preparations. Comparable to Wilcrest in compounding model, regulatory framework, and direct sales to hospital systems.
- QuVa Pharma: QuVa Pharma is a leading FDA-registered 503B outsourcing facility producing sterile compounded preparations for hospital pharmacies. It directly competes with Wilcrest in ready-to-use injectable and hazardous drug compounding, targeting similar customers through enterprise hospital contracts.
- Wedgewood Pharmacy: Wedgewood Pharmacy is a large 503B/503A compounding pharmacy producing customized sterile and non-sterile preparations, including a significant veterinary franchise. Like Wilcrest, it serves hospitals, infusion centers, and veterinary clinics through direct relationships.
Broad incumbents
- Avista Pharma Solutions: Avista Pharma is a contract development and manufacturing organization (CDMO) offering sterile and non-sterile drug product development. Relevant as a comparator for Wilcrest's Contract Development Manufacturing service line and broader CDMO positioning.
- Curium Pharma: Curium is a global nuclear medicine and specialty pharmaceutical manufacturer, with sterile injectable capabilities relevant to oncology and other hospital-administered drugs. Overlaps with Wilcrest on oncology sterile injectables serving hospital systems.
- Central Admixture Pharmacy Services (CAPS / B. Braun): CAPS is a long-established sterile compounding outsourcer owned by B. Braun, supplying compounded admixtures and ready-to-administer preparations to hospital pharmacies nationwide. It competes broadly with Wilcrest but operates at significantly larger scale and as part of a global medical products company.
- Sagent Pharmaceuticals: Sagent is a specialty injectable manufacturer focused on hospital-channel products, including oncology and cardiovascular injectables. Comparable because it supplies the same specialty hospital pharmacy buyers that Wilcrest targets, though as a finished branded/generic manufacturer rather than a compounder.
Regional players
- Letco Medical (Dencare): Letco Medical is a compounding chemicals and supplies distributor and a 503A/503B-adjacent pharmacy services provider, primarily focused on serving independent and regional compounding pharmacies. Comparable where it intersects Wilcrest on raw material sourcing and small-batch compounding support.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks7 records
Key highlights6 records
Customer concentration
Wilcrest Pharma social profiles
Digital presenceWilcrest Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Wilcrest Pharma leadership team
Management profileNumber of profiles
Profiles5 records
Wilcrest Pharma funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Wilcrest Pharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Wilcrest Pharma
What does Wilcrest Pharma do?
Wilcrest Pharma operates an FDA-registered 503B outsourcing facility that formulates complex sterile and non-sterile compounded medications for healthcare organizations. The portfolio spans oncology (antineoplastic) medications, cardiology, ENT, transplant formulations, custom-developed products, and full contract development manufacturing services from formulation research through product release.
Is Wilcrest Pharma a public or private company?
Wilcrest Pharma is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Wilcrest Pharma founded?
Wilcrest Pharma was founded in 2024. It employs 11 to 50 people.
Where is Wilcrest Pharma based?
Wilcrest Pharma is headquartered in Houston, United States, in the North America region.
How does Wilcrest Pharma make money?
One revenue line is on record: compounded Pharmaceutical Products.
Who are Wilcrest Pharma's main competitors?
Direct peers on record are Fagron (503B division, including Pillar5), AnazaoHealth, Stokes Healthcare (Triad), QuVa Pharma and Wedgewood Pharmacy. Broad incumbents are Avista Pharma Solutions, Curium Pharma, Central Admixture Pharmacy Services (CAPS / B. Braun) and Sagent Pharmaceuticals. Letco Medical (Dencare) is listed as a regional player.
Does Wilcrest Pharma have an API?
No public API is recorded for Wilcrest Pharma.
What industry is Wilcrest Pharma in?
Wilcrest Pharma's product category is Compounded Pharmaceutical Manufacturing. Its primary akta.pro industry code is HLAIABAI, Contract Development & Manufacturing for Generics (CDMO/CMO), with a secondary code of HLAIAAAB, Specialty Care Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.